Wie hoch ist der Preis für Bio-Path Holdings, Inc. (BPTH)

Preis für Bio-Path Holdings, Inc. (BPTH) ist $0.035

Wie hoch ist die Marktkapitalisierung für Bio-Path Holdings, Inc. (BPTH)

Marktkapitalisierung für Bio-Path Holdings, Inc. (BPTH) ist $326.98K

Bio-Path Holdings, Inc. (BPTH) KUV

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.

Jahr	P/S-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/S-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/S-Verhältnis	P/S-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	9.88	-	US
Argenx SE ARGX.US	10.30	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.98	-	BE

Unternehmen

P/S-Verhältnis

P/S-Verhältnis-Differenz

Land